Improved Outcomes With Fast Reperfusion in Acute Stroke

Share this content:
Improved Outcomes With Fast Reperfusion in Acute Stroke
Improved Outcomes With Fast Reperfusion in Acute Stroke

FRIDAY, May 20, 2016 (HealthDay News) -- Among patients with acute stroke treated with stent retrievers, fast reperfusion leads to improved functional outcome, according to a study published in the June issue of Radiology.

Mayank Goyal, M.D., from the University of Calgary in Canada, and colleagues examined the correlation between functional independence and time to reperfusion in the Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial. Outcomes were compared in patients treated with intravenous tissue plasminogen activator alone or in combination with the Solitaire device.

The researchers found that a symptom onset to reperfusion time of 150 minutes led to 91 percent estimated probability of functional independence in the stent retriever arm of the study, which decreased by 10 percent over the next hour and by 20 percent with every subsequent hour of delay. From arrival at the emergency department, the time to arterial access was 90 minutes and time to reperfusion was 129 minutes. Compared with patients who presented directly to the endovascular-capable center, patients who initially arrived at a referring facility had longer symptom onset to groin puncture times (275 versus 179.5 minutes; P < 0.001).

"Fast reperfusion leads to improved functional outcome among patients with acute stroke treated with stent retrievers," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Covidien, which funded the SWIFT PRIME trial and manufactures the Solitaire device.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »